DEEJ(SZ:000423) Sou Hu Cai Jing·2025-12-25 09:08Group 1 - The core viewpoint of the article highlights the impressive financial performance of Dong'e Ejiao in the third quarter, with both revenue and profit showing significant growth [1] - In the first three quarters of this year, Dong'e Ejiao achieved a revenue of 4.766 billion yuan, representing a year-on-year increase of 4.41%, and a net profit attributable to shareholders of 1.274 billion yuan, up 10.53% year-on-year [4] - The company has shown a consistent upward trend in revenue and net profit during the tenure of Chairman Cheng Jie, with revenues increasing from 4.042 billion yuan in 2022 to 5.921 billion yuan in 2024 [4] Group 2 - Cheng Jie, who became the chairman of Dong'e Ejiao in 2024, has a strong background in the pharmaceutical industry, having held various positions at China Resources Sanjiu Pharmaceutical and serving as the general manager of Sanofi (Shenzhen) Health Industry [3][4] - Under Cheng Jie's leadership, Dong'e Ejiao's profitability has improved, with the company recording a net profit of 1.557 billion yuan in 2024, reflecting his effective management capabilities [4] - Cheng Jie's compensation increased from 2.804 million yuan in 2022 to 2.661 million yuan in 2023, indicating recognition of his contributions to the company [4]